Neuland Laboratories Limited has announced its financial results for the fourth quarter and the fiscal year ending March 31, 2026, reporting a total income of ₹2053.1 crore. The pharmaceutical company, which specialises in active pharmaceutical ingredients (APIs) and custom manufacturing solutions, highlighted significant growth in its earnings and profitability.
For the quarter ending March 31, 2026, Neuland Laboratories reported a total income of ₹788.7 crore, marking a substantial increase of 134.9% compared to ₹335.8 crore in the same period the previous year. The company’s EBITDA for Q4 FY26 was ₹319.4 crore, a remarkable growth of 448.6% from ₹58.2 crore in Q4 FY25. The EBITDA margin also improved significantly to 40.5% from 17.3% in the prior year, reflecting an increase of 2316 basis points.
Profit before tax (PBT) stood at ₹287.0 crore for the quarter, a 636.6% rise from ₹39.0 crore in Q4 FY25. The PBT margin increased to 36.4% from 11.6%, a jump of 2479 basis points. The company’s profit after tax (PAT) for the quarter was ₹212.5 crore, up 666.3% from ₹27.7 crore in the same quarter last year.
Commenting on the results, Saharsh Davuluri, CEO and Managing Director of Neuland Laboratories, expressed satisfaction with the company’s performance, which was in line with their expectations. He highlighted the company’s focus on execution discipline, customer satisfaction, and business fundamentals as key drivers of growth. Davuluri also mentioned ongoing investments in peptide manufacturing and a new R&D centre as part of the company’s strategy for future growth.
Neuland Laboratories will hold an earnings call on May 12, 2026, at 17:30 IST, where the management will discuss the company’s performance and address questions from participants. The transcript of the call will be made available on the company’s website.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).